IsoRay, Inc. (NYSEAMERICAN:ISR) shares saw unusually-strong trading volume on Wednesday after the company announced better than expected quarterly earnings. Approximately 777,300 shares traded hands during trading, an increase of 407% from the previous session’s volume of 153,379 shares.The stock last traded at $0.37 and had previously closed at $0.34.
The healthcare company reported ($0.01) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. The business had revenue of $2.32 million during the quarter, compared to analysts’ expectations of $2.23 million.
Separately, Zacks Investment Research upgraded shares of IsoRay from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a report on Saturday, September 28th.
The business’s fifty day simple moving average is $0.34 and its 200 day simple moving average is $0.39.
IsoRay Company Profile (NYSEAMERICAN:ISR)
IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.
See Also: What is a balanced fund?
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.